EUVIMEDEUVIMED entdecken
Open Access

Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases

Vlasios S Sotirchos iD, Mikhail T Silk, Juan C Camacho, Emma M Schatoff, Henry S Kunin, Erica S Alexander, Ken Zhao, Louise C Connell, Constantinos T Sofocleous, Nancy E Kemeny

Journal of Gastrointestinal Oncology · 2025-02 · 16 (1) · 92-105

DOI: 10.21037/jgo-24-725 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2025-02. Verfasst von Vlasios S Sotirchos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mitomycin-C is an older drug which has a synergistic mechanism of action with irinotecan. This study evaluated the outcomes of selective intra-arterial mitomycin-C infusions in combination with bi-weekly systemic irinotecan for treatment of liver-dominant metastatic colorectal cancer (CRC) which progressed after hepatic arterial infusion (HAI) pump chemotherapy with floxuridine and at least two lines of systemic chemotherapy.

Methods

An IRB-approved retrospective review of patients receiving at least two sessions of selective monthly mitomycin-C infusions in interventional radiology (IR) was performed. Anatomic and metabolic imaging was initially obtained at 4 weeks after the second infusion, and every 2-3 months thereafter. Response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and European Organization for Research and Treatment of Cancer (EORTC) criteria. Patient, disease and procedural parameters were recorded. Progression-free survival (PFS), liver progression-free survival (LPFS) and overall survival (OS) were assessed with Kaplan Meier methodology.

Results

From January 2019 to April 2023, 46 patients underwent a total of 190 selective infusions (range 2-10; median 4). Twenty-three/46 (50%) patients had KRAS mutations and 35/46 (76.1%) had extrahepatic disease at the time of the first infusion. On initial follow-up, liver disease control was observed in 38/46 using RECIST 1.1 (82.6%; partial response 13%, stable disease 69.6%) and 26/31 using EORTC criteria (83.9%; complete response 6.5%, partial response 48.4%, stable disease 29%). Median PFS, LPFS and OS were 4.1 [95% confidence interval (CI): 3.2-4.9], 5.5 (95% CI: 2.5-8.4) and 9.6 (95% CI: 8.2-11.1) months respectively. The infusions were discontinued in 26 (56.5%) patients due to disease progression. Eighteen patients (39.1%) discontinued the infusion protocol due to toxicities/complications, including hepatic/biliary toxicity (26.1%), hepatic arterial thrombosis (15.2%) and/or pulmonary toxicity (8.7%).

Conclusions

In this heavily pretreated population, addition of intra-arterial mitomycin-C was associated with initial liver disease control rates exceeding 80%. Toxicities were observed, particularly in patients with prolonged disease control who received ≥4 infusions.

Schlagwörter

Stichwörter der Autor:innen

Colorectal liver metastases (CLM)arterially-directed therapieshepatic arterial infusion chemotherapysalvage treatments

Autor:innen und Institutionen

  • Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Interventional Radiology, NYU Langone Health, New York, NY, USA.
  • Department of Clinical Sciences, Florida State University, Sarasota, FL, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Vlasios S Sotirchos

Förderung

  • NCI NIH HHS

Zitieren

APA

Sotirchos, V. S., Silk, M. T., Camacho, J. C., Schatoff, E. M., Kunin, H. S., Alexander, E. S., Zhao, K., Connell, L. C., Sofocleous, C. T., & Kemeny, N. E. (2025). Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases. Journal of Gastrointestinal Oncology, 16(1), 92-105. https://doi.org/10.21037/jgo-24-725

Vancouver

Sotirchos VS, Silk MT, Camacho JC, Schatoff EM, Kunin HS, Alexander ES, et al. Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases. Journal of Gastrointestinal Oncology. 2025;16(1):92-105. doi:10.21037/jgo-24-725

BibTeX
@article{Sotirchos2025,
  author = {Sotirchos, Vlasios S and Silk, Mikhail T and Camacho, Juan C and Schatoff, Emma M and Kunin, Henry S and Alexander, Erica S and Zhao, Ken and Connell, Louise C and Sofocleous, Constantinos T and Kemeny, Nancy E},
  title = {Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {92--105},
  doi = {10.21037/jgo-24-725}
}
Kostenlos starten →